Advertisement

Clinical Implications of the Drug-Centered Approach

  • Sandra Steingard
Chapter

Abstract

This chapter outlines applications of the drug-centered approach to the practice of psychiatry. Some psychiatrists who are critical of the contemporary focus on pharmacotherapy might argue for psychiatrists to return to the era when their primary role was as psychotherapists. That is not the position taken here. Rather, the author proposes that psychiatry should remain the medical specialty whose expertise is in understanding and prescribing psychoactive substances but that its members do so from the perspective of the drug-centered model articulated in Chap.  4. The implications of a drug-centered, as opposed to disease-centered, approach to medications are examined for several major classes of psychoactive compounds. Similar themes emerge: (1) short-term efficacy with increased relapse risk when drugs are stopped, combined with a conceptualization of mental disorders as chronic, commonly leads to recommendations for long-term pharmacotherapy; (2) considerations of possible withdrawal effects are frequently ignored; and (3) each class of drugs is prescribed for ever-widening lists of indications. These factors have contributed to growing numbers of people taking multiple drugs for indefinite durations. The benefits of shifting to a drug-centered approach are explored and the chapter concludes with suggestions for integrating such an approach into psychiatric practice.

Keywords

Psychopharmacology Antipsychotics Antidepressants Psychostimulants Benzodiazepines 

References

  1. 1.
  2. 2.
    Gøtzsche PC. Deadly psychiatry and organized denial. Artpeople. ISBN 978-87-7159-623-6; 2015.Google Scholar
  3. 3.
    Whitaker R. Anatomy of an epidemic. New York: Crown; 2010.Google Scholar
  4. 4.
    Robinson TE, Becker JB. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res Rev. 1986;11(2):157–98.Google Scholar
  5. 5.
    Arnsten AF. Stimulants: therapeutic actions in ADHD. Neuropsychopharmacology. 2006;31:2376–83.PubMedGoogle Scholar
  6. 6.
    Epperson CN, Shanmugan S, Kim DR, et al. New onset executive function difficulties at menopause: a possible role for lisdexamphetamine. Psychopharmacology. 2015;232(16):3091–100.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Moncrieff J. The bitterest pills. London: Palgrave Macmillan; 2013.Google Scholar
  8. 8.
    Nasrallah HA, Tandon R. Classic antipsychotic medication. In: Schatzberg AF, Nemeroff CB, editors. The American psychiatric publishing textbook of psychopharmacology. Washington, DC: American Psychiatric Publishing, Inc.; 2009. p. 533–54.Google Scholar
  9. 9.
    Leucht S, Komossa TM, Heres S, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063–71.PubMedGoogle Scholar
  10. 10.
    Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull. 1991;17(2):325–51.PubMedGoogle Scholar
  11. 11.
    Sisti D, Segal AG, Emanuel EJ. Improving long-term psychiatric care: bring back the asylum. J Am Med Assoc. 2015;313(3):243–5.Google Scholar
  12. 12.
    Chouinard G, Jones BG. Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatr. 1980;137(1):16–21.PubMedGoogle Scholar
  13. 13.
    Samaha AN, Seeman P, Stewart J, et al. “Breakthrough” dopamine supersensitivity during ongoing antipsychotic treatment lead to treatment failure over time. J Neurosci. 2007;27(11):2979–86.PubMedGoogle Scholar
  14. 14.
    Chouinard G, Samaha AN, Chouinard VA, et al. Antipsychotic-induced dopamine supersensitivity psychosis: pharmacology, criteria, and therapy. Psychother Psychosom. 2017;86(4):189–219.PubMedGoogle Scholar
  15. 15.
    Harrow M, Jobe TH, Faull RN. Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis? A 20-year multi-follow-up study. Psychol Med. 2014;44(14):3007–16.PubMedGoogle Scholar
  16. 16.
    Gleeson JF, Cotton SM, Alvarez-Jimenez M, et al. A randomized controlled trial of relapse prevention therapy for first-episode psychosis patients: outcome at 30-month follow-up. Schizophr Bull. 2013;39(2):436–8.PubMedGoogle Scholar
  17. 17.
    Johnstone EC, Macmillan JF, Frith CD, et al. Further investigation of the predictors of outcome following first schizophrenic episodes. Br J Psychiatry. 1990;157:182–9.PubMedGoogle Scholar
  18. 18.
    Wunderink L, Nieboer RM, Wiersma D. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy. JAMA Psychiat. 2013;70(9):913–20.Google Scholar
  19. 19.
    Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering R, Wiersma D. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry. 2007;68(5):654–61.PubMedGoogle Scholar
  20. 20.
    Harding CM, Brooks GW, Ashikaga T, et al. The Vermont longitudinal study of persons with severe mental illness, II: long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia. Am J Psychiatr. 1987;144(6):727–35.Google Scholar
  21. 21.
    Harding CM. Course types in schizophrenia: an analysis of European and American studies. Schizophr Bull. 1988;14(4):633–42.PubMedGoogle Scholar
  22. 22.
    Lehrer DS, Lorenz J. Anosognosia in schizophrenia: hidden in plain sight. Innov Clin Neurosci. 2014;11(5–6):10–7.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Bola JR, Mosher L. Treatment of acute psychosis without neuroleptics: two-year outcomes from the Soteria project. J Nerv Ment Disord. 2003;191(4):219–29.Google Scholar
  24. 24.
    Center for Disease Control. Selected prescription drug classes used in the past 30 days, by sex and age: United States, selected years 1988–1994 through 2011–2014; 2016. https://www.cdc.gov/nchs/hus/contents2016.htm#080. Accessed 05 Aug 2018.
  25. 25.
    Pratt LA, Brody DJ, Gu Q. Antidepressant use among persons aged 12 and over: United States, 2011–2014 NCHS Data Brief 283; 2017. https://www.cdc.gov/nchs/data/databriefs/db283.pdf
  26. 26.
    Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;17:32802–7.Google Scholar
  27. 27.
    Moncrieff J, Kirsch I. Efficacy of antidepressants in adults. Br Med J. 2005;331(7509):155–7.Google Scholar
  28. 28.
    Vittengyl JR. Poorer long-term outcomes among persons with major depressive disorder treated with medication. Psychother Psychosom. 2017;86:302–4.Google Scholar
  29. 29.
    Goldberg D, Privett M, Ustun B, et al. The effects of detection and treatment on the outcome of major depression in primary care: a naturalistic study in 15 cities. Br J Gen Pract. 1998;48:1840–4.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Posternak MA, Soloman DA, Leon AC, et al. The naturalistic course of unipolar major depression in the absence of somatic therapy. J Nerv Ment Dis. 2006;194:324–9.PubMedGoogle Scholar
  31. 31.
    Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatr. 1990;147(2):207–2010.PubMedGoogle Scholar
  32. 32.
    Sharma T, Guski LS, Freund N, et al. Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. Br Med J. 2016;27(352):i65.Google Scholar
  33. 33.
    Kafali N, Progovac A, Hou SS, et al. Long-run trends in antidepressant use among youths after the FDA black box warning. Psychiatr Serv. 2017;69(4):389–95.PubMedGoogle Scholar
  34. 34.
    Safer DJ, Zito JM. Do antidepressants reduce suicide rates? Public Health. 2007;121(4):274–7.PubMedGoogle Scholar
  35. 35.
    Kripke DF. Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of efficacy. F1000Res. 2016;5:918.  https://doi.org/10.12688/f1000research.8729.1. eCollection 2016PubMedGoogle Scholar
  36. 36.
    Lembke A, Papac J, Humphreys K. Our other prescription drug problem. N Engl J Med. 2018;378:693–5.PubMedGoogle Scholar
  37. 37.
    Billioto de Gage S, Moride Y, Ducruet T, et al. Benzodiazepine use and risk of alzheimer’s disease: case-control study. Br Med J. 2014;349:1–10.Google Scholar
  38. 38.
    Kahneman D. Thinking, fast and slow. New York: Farrar, Straus and Giroux; 2011.Google Scholar
  39. 39.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Arlington: American Psychiatric Publishing; 1994.Google Scholar
  40. 40.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013.Google Scholar
  41. 41.
    Harrow M, Jobe TH, Faull RN. Do all schizophrenia patient need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study. Psychol Med. 2012;42(10):2145–55.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Howard CenterBurlingtonUSA
  2. 2.University of Vermont Larner College of MedicineBurlingtonUSA

Personalised recommendations